AR066876A1 - Derivados de amida para inhibir el crecimiento de celulas cancerigenas y una composicion farmaceutica que los comprende. - Google Patents

Derivados de amida para inhibir el crecimiento de celulas cancerigenas y una composicion farmaceutica que los comprende.

Info

Publication number
AR066876A1
AR066876A1 ARP080102395A ARP080102395A AR066876A1 AR 066876 A1 AR066876 A1 AR 066876A1 AR P080102395 A ARP080102395 A AR P080102395A AR P080102395 A ARP080102395 A AR P080102395A AR 066876 A1 AR066876 A1 AR 066876A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
substituted
alkoxy
aryl
Prior art date
Application number
ARP080102395A
Other languages
English (en)
Inventor
Jong Moon Kim
Han Kyong Kim
Keukchan Bang
Bo Im Choi
Young-Gil Ahn
Chang Gon Lee
Mi Young Ko
Maeng Sup Kim
Young Hee Jung
Yun Jung Chae
Kwang-Ok Lee
Mi Young Cha
Se Young Kim
Ki Jeong Lee
Bum Woo Park
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of AR066876A1 publication Critical patent/AR066876A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Derivado de amida y una sal farmacéuticamente aceptable del mismo que inhibe el crecimiento de las células cancerígenas inducido por la sobreexpresion de un receptor del factor de crecimiento epidérmico y también evita el desarrollo de la resistencia a las drogas causado por la mutacion de la EGFR tirosina quinasa, y a una composicion farmacéutica que comprende el mismo como un ingrediente activo. Reivindicacion 1: Un derivado de amida de formula (1) o una sal farmacéuticamente aceptable del mismo: caracterizado porque: A es el grupo de formulas (2) siendo R4, R5, R6 y R7 cada uno independientemente hidrogeno, halogeno, N-alquilo C1-6 o N-hidroxi amido o C-alquilo C1-6 amido inverso(-NHCOC1-6), hidroxicarbonilo (-COOH), alquiloxicarbonilo C1-6 (-COOC1-6) alquilo C1-6, o alquilo C1-6 substituido con un grupo hidroxi, dialquilamina C1-6 o grupo heterocíclico; R1 es un grupo arilo o heterocíclico substituido con uno a cinco X, o alquilo C1-6 substituido con arilo; R2 es hidrogeno, hidroxi, alcoxi C1-6, o alcoxi C1-6 substituido con un grupo alcoxi C1-6 o heterocíclico; R3 es hidrogeno, -COOH, alquiloxicarbonilo C1-6, o amido N-no substituido o N-substituido con Y; na y nb son cada uno un entero que oscila entre 0 y 6; en donde: x es hidrogeno, halogeno, hidroxi, ciano, nitro, (mono-, di-, o trihalogeno)metilo, mercapto, alquiltio C1-6, acrilamido, alquilo C1-6, alquenilo C1-6, alquinilo C1-6, alcoxi C1-6, ariloxi, dialquilamino C1-6, o alquilo C1-6 o alcoxi C1-6 substituido con Z, con la condicion de que cuando el numero de X es dos o más, los grupos X pueden fusionarse entre sí para formar una estructura de anillo; Y es hidroxi, alquilo C1-6 o alquilo C1-6 substituido con Z, conteniendo el alquilo C1-6 una a cuatro de la parte seleccionada entre el grupo que consiste en N, O, S, SO y SO2 y Z es un grupo alquilo C1-6, arilo o heterocíclico, siendo dicho grupo arilo un grupo aromático monocíclico o bicíclico C5-12, siendo dicho grupo heterocíclico un grupo aromático o no aromático monocíclico o bicíclico C5-12 que contiene una a cuatro de la parte seleccionada entre el grupo que consiste en N, O, S, SO y SO2 y siendo dichos grupos arilo y heterocíclico no substituidos o substituidos con substituyente seleccionados entre el grupo que consiste en halogeno, hidroxilo, amino, nitro, ciano, alquilo C1-6, alquenilo C1-6, alquinilo C1-6, alcoxi C1-6, monoalquilamino C1-6 y dialquilamino C1-6.
ARP080102395A 2007-06-05 2008-06-05 Derivados de amida para inhibir el crecimiento de celulas cancerigenas y una composicion farmaceutica que los comprende. AR066876A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20070054997 2007-06-05

Publications (1)

Publication Number Publication Date
AR066876A1 true AR066876A1 (es) 2009-09-16

Family

ID=40094307

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080102395A AR066876A1 (es) 2007-06-05 2008-06-05 Derivados de amida para inhibir el crecimiento de celulas cancerigenas y una composicion farmaceutica que los comprende.
ARP170103011A AR110003A2 (es) 2007-06-05 2017-10-30 Derivado de amida

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170103011A AR110003A2 (es) 2007-06-05 2017-10-30 Derivado de amida

Country Status (25)

Country Link
US (1) US8188102B2 (es)
EP (1) EP2167492B1 (es)
JP (1) JP5155391B2 (es)
KR (1) KR101013319B1 (es)
CN (1) CN101679384B (es)
AR (2) AR066876A1 (es)
AU (1) AU2008260772B2 (es)
BR (1) BRPI0811069B1 (es)
CA (1) CA2687180C (es)
DK (1) DK2167492T3 (es)
ES (1) ES2558623T3 (es)
HK (1) HK1142591A1 (es)
HR (1) HRP20160007T1 (es)
HU (1) HUE028243T2 (es)
IL (1) IL202154A (es)
MX (1) MX2009012772A (es)
MY (1) MY144972A (es)
NZ (1) NZ582412A (es)
PL (1) PL2167492T3 (es)
PT (1) PT2167492E (es)
RU (1) RU2434010C2 (es)
TW (1) TWI377944B (es)
UA (1) UA96045C2 (es)
WO (1) WO2008150118A2 (es)
ZA (1) ZA201000022B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
SG174774A1 (en) 2006-09-11 2011-10-28 Curis Inc Quinazoline based egfr inhibitors containing a zinc binding moiety
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
ES2659725T3 (es) 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. Inhibidores de EGFR y procedimiento de tratamiento de trastornos
KR101217526B1 (ko) * 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR101272613B1 (ko) * 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
CA2861010A1 (en) 2012-01-13 2013-07-18 Xiao Xu Heterocyclic compounds and uses as anticancer agents
CN104080774B (zh) 2012-01-17 2017-02-22 安斯泰来制药株式会社 吡嗪甲酰胺化合物
CN102659764A (zh) * 2012-04-16 2012-09-12 中国科学院广州生物医药与健康研究院 酪氨酸激酶不可逆抑制剂及其制备方法和用途
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
CA2917364C (en) 2013-07-11 2020-09-29 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
WO2015154725A1 (zh) * 2014-04-11 2015-10-15 四川海思科制药有限公司 喹唑啉衍生物及其制备方法和在医药上的应用
JP6769962B2 (ja) * 2014-12-03 2020-10-14 オークランド ユニサービシーズ リミティド 癌治療のためのキナーゼ阻害剤プロドラッグ
US10231973B2 (en) * 2015-03-20 2019-03-19 Chai Tai Tianqing Pharmaceutical Group Co., Ltd. Salts of quinazoline derivative and method for preparing the same
CA3001744A1 (en) 2015-10-09 2017-04-13 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
JP7036798B2 (ja) * 2016-08-25 2022-03-15 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 キナゾリン誘導体の塩の結晶
CN108069946B (zh) * 2016-11-08 2020-06-05 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的取代的喹唑啉化合物
US10898487B2 (en) 2016-12-22 2021-01-26 Boehringer Ingelheim International Gmbh Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
US10981900B2 (en) 2017-02-28 2021-04-20 Medshine Discovery Inc. Spiro compound and use thereof
JP2020516682A (ja) 2017-04-07 2020-06-11 エイシア セラピューティクス， インコーポレイテッド ピロロピリミジンキナーゼの薬学的な塩、物理的形態および組成物、ならびにその作製方法
JP7128204B2 (ja) * 2017-04-27 2022-08-30 アストラゼネカ・アクチエボラーグ Ｃ５－アニリノキナゾリン化合物及び癌の処置におけるそれらの使用
AR113451A1 (es) * 2017-10-18 2020-05-06 Spectrum Pharmaceuticals Inc Inhibidores de tirosina quinasas de la familia de los egfr mutantes
US20210078958A1 (en) 2017-12-19 2021-03-18 Medshine Discovery Inc. Quinazoline derivative and use thereof
SG11202005881YA (en) 2017-12-21 2020-07-29 Boehringer Ingelheim Int Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
WO2019191279A2 (en) 2018-03-27 2019-10-03 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
WO2019223671A1 (zh) * 2018-05-24 2019-11-28 深圳市塔吉瑞生物医药有限公司 取代的氨基喹唑啉类化合物及其药物组合物及其用途
CN110577514B (zh) * 2018-06-08 2022-07-05 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
WO2019233459A1 (zh) * 2018-06-08 2019-12-12 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
CN108623490A (zh) * 2018-06-22 2018-10-09 苏州市贝克生物科技有限公司 (2z)-4-(二甲基氨基)-2-丁烯酸盐酸盐的合成方法
TW202019412A (zh) 2018-06-25 2020-06-01 美商光譜製藥公司 波齊替尼(poziotinib)與細胞毒性劑及／或其他分子靶向劑之組合及其用途
TW202012391A (zh) * 2018-07-04 2020-04-01 日商第一三共股份有限公司 二芳基醚型喹唑啉衍生物
CA3111062A1 (en) * 2018-09-14 2020-03-19 Hanmi Pharmaceutical Co., Ltd. Crystalline forms of a quinazole compound and its hydrochloride salts
KR20210066841A (ko) * 2018-09-21 2021-06-07 스펙트럼 파마슈티컬즈 인크 신규한 퀴나졸린 egfr 억제제
CN113382986A (zh) 2018-09-25 2021-09-10 黑钻治疗公司 酪氨酸激酶抑制剂组合物、其制备方法和使用方法
KR101950942B1 (ko) * 2019-01-28 2019-02-22 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
CN115838369A (zh) 2019-03-19 2023-03-24 株式会社沃若诺伊 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物
CA3137901A1 (en) * 2019-04-25 2020-10-29 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of tyrosine kinase
US20220220440A1 (en) 2019-05-09 2022-07-14 FUJIFILM Cellular Dynamics, Inc. Methods for the production of hepatocytes
WO2020253836A1 (zh) 2019-06-19 2020-12-24 南京明德新药研发有限公司 喹唑啉类化合物的晶型、盐型及其制备方法
WO2020262998A1 (ko) * 2019-06-26 2020-12-30 한미약품 주식회사 항 종양 활성을 갖는 신규 퀴나졸린 유도체 및 이를 포함하는 약학 조성물
KR20210049004A (ko) 2019-10-24 2021-05-04 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체를 포함하는 약제학적 제제 및 이를 포함하는 약제학적 제품
WO2021127397A1 (en) * 2019-12-19 2021-06-24 Black Diamond Therapeutics, Inc. Nitrogen heterocyclic compounds and methods of use
EP4097140A4 (en) * 2020-01-29 2023-10-18 Board of Regents, The University of Texas System USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS TO TREAT CANCER WITH NRG1 FUSIONS
WO2021231400A1 (en) * 2020-05-12 2021-11-18 Accutar Biotechnology, Inc. Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors
CN111763215B (zh) * 2020-07-21 2021-05-18 成都海博为药业有限公司 一种具有含氮杂环结构的化合物及其制备方法和用途
CN115803326B (zh) * 2020-11-23 2024-03-26 上海和誉生物医药科技有限公司 Egfr抑制剂及其制备方法与在药学上的应用
WO2022170043A1 (en) * 2021-02-05 2022-08-11 Accutar Biotechnology, Inc. Quinazoline derived compounds as egfr inhibitors and their uses thereof
JP2024523861A (ja) 2021-06-15 2024-07-02 ジェネンテック， インコーポレイテッド がんを処置するための併用療法におけるｅｇｆｒ阻害剤およびｐｅｒｋ活性化剤、ならびにこれらの使用
WO2022266427A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 4-(aryl-methyl-amino)-quinazoline derivatives and uses thereof
WO2022266426A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 6-(heterocycloalkyl-oxy)-quinazoline derivatives and uses thereof
CA3229692A1 (en) * 2021-08-24 2023-03-02 Shunqi Yan Quinazoline compounds for treatment of disease
CN115894486B (zh) * 2021-09-30 2024-02-09 北京赛特明强医药科技有限公司 一种氢化吡啶并喹唑啉类化合物、组合物及其应用
WO2023128350A1 (ko) * 2021-12-30 2023-07-06 주식회사 비투에스바이오 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2024083120A1 (zh) * 2022-10-18 2024-04-25 南京明德新药研发有限公司 苄氨基喹啉类化合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
AU2003226705B2 (en) 2002-03-30 2008-11-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
UY28441A1 (es) * 2003-07-29 2005-02-28 Astrazeneca Ab Derivados de quinazolina
CN1882573A (zh) * 2003-09-16 2006-12-20 阿斯利康(瑞典)有限公司 作为酪氨酸激酶抑制剂的喹唑啉衍生物
BRPI0414735A (pt) 2003-09-25 2006-11-21 Astrazeneca Ab derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
US7687502B2 (en) 2004-03-23 2010-03-30 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
US20100234371A1 (en) * 2005-08-22 2010-09-16 Frank Himmelsbach Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
WO2007055513A1 (en) * 2005-11-08 2007-05-18 Hanmi Pharm. Co., Ltd. Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof

Also Published As

Publication number Publication date
HUE028243T2 (en) 2016-12-28
JP2010529115A (ja) 2010-08-26
WO2008150118A2 (en) 2008-12-11
IL202154A (en) 2014-05-28
HK1142591A1 (en) 2010-12-10
TWI377944B (en) 2012-12-01
PT2167492E (pt) 2016-02-04
AU2008260772A1 (en) 2008-12-11
AR110003A2 (es) 2019-02-13
EP2167492A2 (en) 2010-03-31
BRPI0811069B1 (pt) 2022-08-30
HRP20160007T1 (hr) 2016-02-12
RU2009149307A (ru) 2011-07-20
RU2434010C2 (ru) 2011-11-20
KR20080107294A (ko) 2008-12-10
KR101013319B1 (ko) 2011-02-09
CA2687180C (en) 2012-07-24
WO2008150118A3 (en) 2009-01-29
CA2687180A1 (en) 2008-12-11
BRPI0811069A2 (pt) 2014-12-09
NZ582412A (en) 2011-12-22
TW200906414A (en) 2009-02-16
DK2167492T3 (en) 2016-01-11
IL202154A0 (en) 2010-06-16
US8188102B2 (en) 2012-05-29
EP2167492B1 (en) 2015-10-14
JP5155391B2 (ja) 2013-03-06
US20100179120A1 (en) 2010-07-15
UA96045C2 (ru) 2011-09-26
ES2558623T3 (es) 2016-02-05
ZA201000022B (en) 2011-04-28
MX2009012772A (es) 2009-12-15
AU2008260772B2 (en) 2011-06-02
CN101679384B (zh) 2013-10-16
EP2167492A4 (en) 2010-12-15
CN101679384A (zh) 2010-03-24
MY144972A (en) 2011-11-30
PL2167492T3 (pl) 2016-03-31

Similar Documents

Publication Publication Date Title
AR066876A1 (es) Derivados de amida para inhibir el crecimiento de celulas cancerigenas y una composicion farmaceutica que los comprende.
BR112021012635A2 (pt) Compostos de 3-carbonilamino-5-ciclopentil-1 fi-pirazol tendo atividade inibitória sobre cdk2
CR20120217A (es) Derivados de la cromenona con actividad anti-tumoral
NO20075623L (no) Benzodioksan- og benzodioksolanderivater og deres anvendelse
CO5560573A2 (es) Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen
AR062292A1 (es) Derivados de pirrolo (2,3 d) pirimidina como inhibidor de pi3k, composiciones farmaceuticas y usos de los mismos
AR036107A1 (es) Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi
UY30183A1 (es) Derivados de quinolina
AR069772A1 (es) Derivados heterociclicos, una composicion farmaceutica y un juego que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de una infeccion parasitaria.
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
BRPI0519474A2 (pt) derivados de quinazolina para inibir o crescimento de cÉlulas cancerosas e mÉtodo para a preparaÇço destes
ECSP024393A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
BRPI0713132B8 (pt) compostos derivados de cinamoil-piperazina, método de preparação dos referidos compostos, composições farmacêuticas, seus usos como antagonistas de par-i e produtos
BRPI0410720A (pt) quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
PE20081314A1 (es) COMPUESTOS TRICICLICOS FUSIONADOS NO ESTEROIDALES COMO MODULADORES DEL RECEPTOR GLUCOCORTICOIDE, AP-1 Y/O ACTIVIDAD NF-kB
NI200700316A (es) Aminopirimidinas como moduladores de la cinasa
SV2003001148A (es) Derivados de benzamida tiazol y composciones farmaceuticas para inhibir la proliferacion de celulas, y metodos para su utilizacion ref. no.0097-01-sv
UY30874A1 (es) Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapéutica.
AR067390A1 (es) Imidazoles trisustituidos, un proceso para su elaboracion, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el antagonismo de los receptores ccr
TW200643015A (en) 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
ECSP066588A (es) Tiazolidinonas, su preparación y su uso como medicamentos
UY29145A1 (es) 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y su uso como medicamentos
EA200800018A1 (ru) Аминопиримидины в качестве модуляторов киназы

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FG Grant, registration